Engineered Nanoparticle Applications for Recombinant Influenza Vaccines
- Zachary R. Sia
Zachary R. SiaDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United StatesMore by Zachary R. Sia
- ,
- Matthew S. Miller
Matthew S. MillerDepartment of Biochemistry and Biomedical Sciences, Michael G. DeGroote Institute for Infectious Diseases Research, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario L8S 4L8, CanadaMore by Matthew S. Miller
- , and
- Jonathan F. Lovell*
Jonathan F. Lovell*Email: [email protected]Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United StatesMore by Jonathan F. Lovell
Abstract
Influenza viruses cause seasonal epidemics and represent a pandemic risk. With current vaccine methods struggling to protect populations against emerging strains, there is a demand for a next-generation flu vaccine capable of providing broad protection. Recombinant biotechnology, combined with nanomedicine techniques, could address this demand by increasing immunogenicity and directing immune responses toward conserved antigenic targets on the virus. Various nanoparticle candidates have been tested for use in vaccines, including virus-like particles, protein and carbohydrate nanoconstructs, antigen-carrying lipid particles, and synthetic and inorganic particles modified for antigen presentation. These methods have yielded some promising results, including protection in animal models against antigenically distinct influenza strains, production of antibodies with broad reactivity, and activation of potent T cell responses. Based on the evidence of current research, it is feasible that the next generation of influenza vaccines will combine recombinant antigens with nanoparticle carriers.
KEYWORDS:
Cited By
This article is cited by 14 publications.
- Chunhong Dong, Ye Wang, Wandi Zhu, Yao Ma, Joo Kim, Lai Wei, Gilbert X. Gonzalez, Bao-Zhong Wang. Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice. ACS Applied Materials & Interfaces 2022, 14 (5) , 6331-6342. https://doi.org/10.1021/acsami.1c19192
- Kanza Rahali, Atabak Ghanizadeh Tabriz, Dennis Douroumis. The effect of 3D printed microfluidic array designs on the preparation of liposome nanoparticles. Journal of Drug Delivery Science and Technology 2024, 94 , 105411. https://doi.org/10.1016/j.jddst.2024.105411
- Zachary R. Sia, Jayishnu Roy, Wei-Chiao Huang, Yiting Song, Shiqi Zhou, Yuan Luo, Qinzhe Li, Dominic Arpin, Hilliard L. Kutscher, Joaquin Ortega, Bruce A. Davidson, Jonathan F. Lovell. Adjuvanted nanoliposomes displaying six hemagglutinins and neuraminidases as an influenza virus vaccine. Cell Reports Medicine 2024, 5 (3) , 101433. https://doi.org/10.1016/j.xcrm.2024.101433
- Muzammil Hussain, Noman Shakoor, Muhammad Adeel, Muhammad Arslan Ahmad, Haichao Zhou, Zhiyong Zhang, Ming Xu, Yukui Rui, Jason C. White. Nano-enabled plant microbiome engineering for disease resistance. Nano Today 2023, 48 , 101752. https://doi.org/10.1016/j.nantod.2023.101752
- Tean Zaheer, Afshan Muneer, Amjad Islam Aqib, Kaushik Pal, Maheen Murtaza, Mahreen Fatima, Muhammad Saad, Kashif Prince. Concluding Remarks on Target Nanomedicine: Present and Future Aspects. 2023, 343-361. https://doi.org/10.1007/978-3-031-35395-6_19
- Wen-Chien Wang, Ekramy E. Sayedahmed, Suryaprakash Sambhara, Suresh K. Mittal. Progress towards the Development of a Universal Influenza Vaccine. Viruses 2022, 14 (8) , 1684. https://doi.org/10.3390/v14081684
- Luis Jiménez-Cabello, Sergio Utrilla-Trigo, Natalia Barreiro-Piñeiro, Tomás Pose-Boirazian, José Martínez-Costas, Alejandro Marín-López, Javier Ortego. Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance. Vaccines 2022, 10 (7) , 1124. https://doi.org/10.3390/vaccines10071124
- Chunhong Dong, Bao-Zhong Wang. Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats. Advanced NanoBiomed Research 2022, 2 (3) https://doi.org/10.1002/anbr.202100122
- Lukas Käßer, Julie Harnischfeger, Denise Salzig, Peter Czermak. The effect of different insect cell culture media on the efficiency of protein production by Spodoptera frugiperda cells. Electronic Journal of Biotechnology 2022, 56 , 54-64. https://doi.org/10.1016/j.ejbt.2022.01.004
- Atin Khalaj-Hedayati, Caroline Lin Lin Chua, Peter Smooker, Khai Wooi Lee. Universal influenza vaccine technologies and recombinant virosome production. 2022, 45-89. https://doi.org/10.1016/bs.mim.2022.04.001
- Sofia B. Carvalho, Cristina Peixoto, Manuel J. T. Carrondo, Ricardo J. S. Silva. Downstream processing for influenza vaccines and candidates: An update. Biotechnology and Bioengineering 2021, 118 (8) , 2845-2869. https://doi.org/10.1002/bit.27803
- Zachary R. Sia, Xuedan He, Ali Zhang, Jann C. Ang, Shuai Shao, Amal Seffouh, Wei-Chiao Huang, Michael R. D’Agostino, Amir Teimouri Dereshgi, Sambhara Suryaprakash, Joaquin Ortega, Hanne Andersen, Matthew S. Miller, Bruce A. Davidson, Jonathan F. Lovell. A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge. Proceedings of the National Academy of Sciences 2021, 118 (22) https://doi.org/10.1073/pnas.2025759118
- Chunhong Dong, Ye Wang, Gilbert X. Gonzalez, Yao Ma, Yufeng Song, Shelly Wang, Sang-Moo Kang, Richard W. Compans, Bao-Zhong Wang. Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains. Proceedings of the National Academy of Sciences 2021, 118 (19) https://doi.org/10.1073/pnas.2024998118
- Peter D. Kwong, Brandon J. DeKosky, Jeffrey B. Ulmer. Antibody-guided structure-based vaccines. Seminars in Immunology 2020, 50 , 101428. https://doi.org/10.1016/j.smim.2020.101428